

Rec'd PCT/PTO 20 JUL 2004

PCT/GB 2003 / U U U 3 0 1

10/581808



INVESTOR IN PEOPLE



**PRIORITY
DOCUMENT**

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 25 MAR 2003

WIPO

PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated

18 February 2003

BEST AVAILABLE COPY

Patents Form 1/77

Patents Act 1977
e (6)

24 JAN 2002

Request for grant of a patent

(the notes on the back of this form. You can also
an explanatory leaflet from the Patent Office to
you fill in this form)

**The
Patent
Office**

25 JAN 2002 06:00-2-000013
01/7/80 0.00-0201607.9

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference

P029491GB

2. Patent application number
(The Patent Office will fill in this part)

0201607.9

3. Full name, address and postcode of the or of
each applicant (underline all surnames)

Michael John Desmond Gamlen
9 Aldersmead Road
Beckenham
Kent
BR3 1NA

(For further applicant, please see continuation sheet)

Patents ADP number (if you know it)

If the applicant is a corporate body, give the
country/state of its incorporation

8310898001

4. Title of the invention

Formulation for the Administration of Medicinal Substances

5. Name of your agent (if you have one)

Carpmaels & Ransford

"Address for service" in the United Kingdom
to which all correspondence should be sent
(including the postcode)

43 Bloomsbury Square
London
WC1A 2RA

Patents ADP number (if you know it)

83001

6. If you are declaring priority from one or more
earlier patent applications, give the country
and the date of filing of the or of each of these
earlier applications and (if you know it) the or
each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise
derived from an earlier UK application,
give the number and the filing date of
the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right
to grant of a patent required in support of
this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an
applicant, or
- c) any named applicant is a corporate body

No

See note (d))

Patents Form 1/77

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

1 ✓

Description

8 ✓

Claim(s)

2 ✓

Abstract

1 ✓

Drawing(s)

0

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature *Carpmaels & Ransford* Date

Carpmaels & Ransford

24th January 2002

12. Name and daytime telephone number of person to contact in the United Kingdom

Mr Peter M. Johnston

020-7242 8692

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- b) Write your answers in capital letters using black ink or you may type them.
- c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- e) Once you have filled in the form you must remember to sign and date it.
- f) For details of the fee and ways to pay please contact the Patent Office.

P029491GB

Nicholas John Heightman
51 Broom Close
Teddington
Middlesex.
TW11 9RL

83 109 14001

FORMULATION FOR THE ADMINISTRATION OF MEDICINAL SUBSTANCES

FIELD OF INVENTION

This invention relates to a new formulation for the administration of medicinal substances within traditional baked food products, in particular within sandwich biscuits.

BACKGROUND OF THE INVENTION

Many medicines are potent materials requiring small amounts for their effectiveness, but there are other medicines that must be administered in large doses. Conventional formulations such as tablets and capsules can accommodate up to 1000mg of active ingredient but the products are very large and many patients find them difficult to swallow. In many cases the physical properties of the medicinal substance preclude dosages in excess of 250-500mg as they require dilution in inert materials to render them suitable for processing. Dosages of the order of several or many grammes per day require the patient to take many tablets. Some medicines such as guar gum and cholestyramine resin are presented in sachets for dispersion in water. The products are not very palatable and are inelegant, again resulting in problems with patient acceptability and compliance.

It is known that medicines can be made more palatable or their presence disguised by incorporating the medicines within pre-cooked biscuits that have been reduced to crumb form. However, this requires intervention on behalf of the person making up the mixture and relies on their skill in ensuring that both a full dose of medicine is incorporated within the mixture and that the patient consumes all of the mixture. It is also known that certain therapeutic substances can be incorporated within biscuits during the initial cooking step, but this is not always satisfactory, particularly if the incorporated substance is adversely affected by the cooking process. There thus remains a need to provide alternative formulations for unpalatable medicinal, i.e. pharmaceutically active, substances.

It is the purpose of the present invention to allow the inclusion of active medicinal substances in readily acceptable formulations in such a way that compliance with drug treatment dosage regimes is enhanced. The present invention also addresses the problem of allowing large dosages of drugs to be administered effectively, especially as it has often not previously been convenient to administer such dosages by known administration routes. Many treatment regimes achieve sub-optimal therapeutic results because patients for whom the treatment is prescribed find that it is unpleasant to take the drug in the

amount required and accordingly the patient may either omit taking doses or take them in inadequate quantities. The present invention permits the administration of large amounts of unpalatable material - for example with a gritty texture or a chalky texture or other unpleasant mouth feel, in a product which both palatable and familiar to the patient. This
5 helps to ensure acceptability to the patient, and thereby improve patient compliance.

We have found that the formulation according to the present invention can be adapted to carry relatively high quantities of medicinal drug substances and combination of medicinal substances in such a way that chewing in the mouth facilitates swallowing without adversely affecting the taste or mouthfeel of the biscuit. This makes the
10 administration of drugs much more acceptable to many patients who find it difficult to swallow conventional pills and capsules. A further advantage is that formulations of the present invention have a texture that masks unpleasant mouth feel, such as gritty texture or chalkiness of some medicinal substances. The new formulations are also particularly suitable for the long-term administration of medicinal substances.

15

SUMMARY OF THE INVENTION

According to the present invention there further provided a formulation for the administration of a medical substance comprising a sandwich biscuit having two or more biscuit layers that support filler layer(s), in which the filler layer, and optionally the biscuit
20 layers, comprise(s) a dosage unit form, or a multiple or sub-multiple thereof, of an unpalatable medicament. A further aspect of the invention is that the filler layer can contain a large amount of medicinal substance without having a deleterious effect on the mouth feel or palatability of the product.

The "sandwich biscuit" of the present invention may comprise a cream or other
25 filling layer supported between any convenient number of dry layers, normally two layers, of biscuit. The biscuit layer of the sandwich biscuit may be a plain, non-medicated, biscuit layer or may itself contain a medicament. In the latter instance, it is possible to select a different medicament for the filler layer from that in the biscuit layer, whereby the two medicaments have a co-operating or synergistic effect. As already indicated, a medicine is
30 unpalatable if it cannot be readily orally administered in its simple state, for example because of unpleasant mouth feel.

As indicated previously, the invention is of special value where relatively large amounts of active medicinal ingredient need be taken for the treatment to be effective, for

example an individual dose in excess of 250 mg, particularly in excess of 500mg. Large amounts of medicament includes quantities between 1g and 3g per portion, although even higher quantities may be used in some circumstances. This feature of the invention can be particularly useful in both human and veterinary medicine.

5 The biscuits of the present invention would normally be subjected to a single cooking process and are otherwise known as cookies. Originally biscuits were subjected to two baking steps with the biscuit being dried in the second step. A rusk or similar product such as ships biscuits would be the result. Although such biscuits are long lasting, the second cooking step would normally be avoided in the present invention to prevent thermal
10 damage to the medicinal compound and to make the product more palatable. Nevertheless, special technical steps must be taken to preserve the freshness of biscuits of the present invention as a considerably longer shelf life is contemplated for pharmaceuticals. For example, pharmaceuticals are often stored for up to 18 months, whereas baked products are normally consumed within a few weeks at the most. Appropriate steps for the long-term
15 preservation of medical biscuits according to the invention might be the incorporation of suitable preservative substances or the use of specialised packaging materials to prevent the ingress of moisture and oxygen. Of course there may be occasions when it would be appropriate to store the medicated filling separately and arrange for the formation of the sandwich biscuit close to the anticipated date of consumption.

20 The sandwich biscuit embodiment of the present invention in which the medicament is only in the filling layer would be adopted if the medicament is heat sensitive and cannot be incorporated in the biscuit composition during the cooking stage without degradation.

 The biscuits of the present invention would normally be prepared within food
25 factories where the existing strict hygiene and quantity monitoring would be easily adapted to the strict requirements of the pharmaceutical industry. The various techniques for biscuit making on the domestic scale are generally adaptable to factory scale production. The main criterion for the suitability of a particular technique is the need to ensure that the weight and thus dosage of the individual portions of the resulting cooked biscuits can be
30 tightly controlled. Examples of appropriate techniques are dropped cookies where soft dough is spooned directly on to the baking sheet in predetermined portions, shaped cookies where a predetermined portion is cut from soft dough, piped cookies where a relatively

fluid mixture is piped onto a baking tray and bar cookies, such as flapjacks, in which a large block is produced and then cut after cooking into suitably sized portions.

Biscuit formulations can be prepared from a number of conventional ingredients and it is possible to select particular ingredients on the basis of their appropriateness to the disease to be treated. For example, if cholesterol reduction were the object of the therapy it would be possible to base a biscuit on a formulation on oats, which is a material that is believed to have additional therapeutic effect in lowering cholesterol. Such a biscuit layer would then be used in conjunction with a cholesterol lowering medicament in the filling layer.

10 In one embodiment the present invention accordingly provides a sandwich biscuit in which the medicinal substance in the biscuit and the medicament in the filler layer have a co-operating or synergistic effect on administration.

For the treatment of renal failure, sandwich biscuits contain an ion exchange resin substance VML252 with, or without a combination of calcium carbonate in the filler layer, or in both filler and biscuit layers, would be appropriate. This formulation would be used to treat elevated blood phosphate levels encountered by patients undergoing renal dialysis. This is one of the instances mentioned previously in which very high dosages of medicines are required and are difficult to present to the patient in an acceptable form in other ways. The presence of the medicament in both layers would be particularly appropriate in this instance. A typical dosage for the administration of such ion exchange resins would be approximately 8-12 g/day. Other treatments for hyperphosphataemia such as lanthanum carbonate and sevelamer hydrochloride (Renagel)

As already indicated, lowering cholesterol levels is also a possible treatment and sandwich biscuits for this purpose may contain the ion exchange resin, cholestyramine with, or without, other active substances including chlofibrate, gemfibrozil and other orally active cholesterol-lowering materials. Again high dosages may be necessary and a dosage of approximately 12g/day of cholestyramine is typical.

Worm control in pets and farm animals may be based on sandwich biscuits formulated comprising anthelmintic agents for example, albendazole, febendazole (Panacura®), Ivermectin, thiabendazole and other bendazole substances. Appropriate version of such anthelmintic formulations also may be used in human medicine.

For the treatment of diabetes type 2, sandwich biscuit formulation containing metformin or combinations of other oral agents with metformin would be appropriate, as

would biscuit formulations with gamma guanidinobutyramide and its pharmaceutically acceptable salts together with combinations of other agents used to treat diabetes type 2. Appropriate dosages of these active ingredients would be 200 to 2000mg.

Where a patient suffers from excessive serum potassium, sandwich biscuit formulations containing the ion exchange resin and combinations of other oral agents used for treating elevated serum potassium would be appropriate.

The following examples are provided to further illustrate the present invention

Example 1

A semi-sweet biscuit enriched with calcium carbonate is prepared from the following ingredients:

Plain flour	250g
Sugar	50g
Margarine	40g
Salt	3g
Calcium carbonate	53g
Water to mix	110g

The flour, salt and calcium carbonate are mixed together and the margarine rubbed in until the mixture resembles fine breadcrumbs. Water is added to form a firm dough, which is rested for 15 minutes. The dough is rolled to a thickness of about 2 mm and cut into circles weighing 7.5g, so that each baked biscuit contains approximately 1g of calcium carbonate.

The biscuits are baked on a greased baking sheet in a pre-heated oven at 190°C for 5 minutes until a pale golden brown colour. The biscuits are then removed from the oven and allowed to cool.

The cream-filling is prepared using a cream made from the following ingredients:

Icing sugar	237g
Fat	240g
Lecithin	0.6g
Salt	0.3g
Vanilla liquid essence	1.8g
Calcium carbonate	120g

The ingredients are mixed together to form a cream filling of which 5g, containing 1g calcium carbonate, is deposited between two semi sweet biscuits, prepared as described

above. This provides a total dose of 3g calcium carbonate per biscuit. The biscuits are stored in an airtight container.

Example 2

A digestive biscuit enriched with calcium carbonate may be prepared from the following ingredients:

	Plain flour	160g
	Wheatmeal flour	45g
	Margarine	65g
	Caster sugar	15g
10	Demerara sugar	35g
	Golden syrup	15g
	Calcium carbonate	30g
	Salt	2g
	Water	50g

15 The margarine, sugars and syrup are creamed together for 3 minutes and the dry ingredients folded into the resultant mixture. Water is added to form a firm dough, which is rested for 15 minutes. The dough is rolled to a thickness of about 3mm and cut into circles weighing 14g, so that each baked biscuit contains approximately 1g of calcium carbonate.

20 The biscuits are baked on a greased baking sheet in a pre-heated oven at 185°C for 6 minutes until a golden brown colour. The biscuits are then removed from the oven and allowed to cool.

A cream filling prepared as described in Example 1 is deposited between two biscuits. This provides a total dose of 3g calcium carbonate per biscuit. The biscuits are stored in an airtight container.

Example 3

A semi-sweet biscuit that may contain an ion exchange resin VML 252 may be prepared from the following ingredients:

	Flour	500g
30	Sugar	104g
	Fat	80g
	Glucose	6.5g
	Salt	6g

Sodium bicarbonate	2.5g
Ammonium bicarbonate	5g
VML 252	107g
Water to mix	220g

- 5 The dough is mixed until reaching a temperature of 40°C. The VML 252 is added to the dough mix and mixed until evenly distributed.

The dough is rested for 15 minutes before sheeting to a thickness of 3mm and cut into circles weighing 7.5g, so that each baked biscuit contains approximately 1g of VML 252.

- 10 The biscuits are baked on a greased baking sheet in a pre-heated oven at 190°C for 5.5 minutes until a pale golden brown colour. After being removed from the oven and allowed to cool, the biscuits are stored in an airtight container.

The cream-filling is prepared using a cream made from the following ingredients:

	Icing sugar	237g
15	Fat	240g
	Lecithin	0.6g
	Salt	0.3g
	Vanilla liquid essence	1.8g
	VML 252	120g

- 20 The ingredients are mixed together to form a cream filling of which 5g, containing 1g VML 252, is deposited between two semi sweet biscuits, prepared as in Example 5. This provides a total dose of 3g VML 252 per biscuit. The biscuits are stored in an airtight container.

Example 4

- 25 A low salt snack cracker is prepared from the following ingredients:

	Fat (reduced fat spread rich in monounsaturates)	160g
	Salt	13g
	Skimmed milk powder	16g
30	Flour	800g
	Ammonium bicarbonate	20g
	Sodium metabisulphite	10g
	Water	450g

The ingredients are added in the above order and blended together for 1 minute. The dough is then mixed at 120 rpm for 3.5 minutes. The dough is rested for 15 minutes before sheeting and laminating to a final thickness of 2mm.

The dough is cut into circles weighing 8g. The crackers are baked at 230°C for 4.5 minutes. After being removed from the oven and allowed to cool.

A cream cheese filling containing gamma guanidinobutyramide (an antidiabetic agent) was prepared using a cream made from the following ingredients:

	Fat (reduced fat spread rich in monounsaturates)	240g
10	Lecithin	0.6g
	Cheese flavouring	2.0g
	Gamma guanidinobutyramide	2.0g

The cream filling is added between two biscuit layers in an amount that provides 200 to 2000mg of gamma guanidinobutyramide per sandwich biscuit. The biscuits are then stored in an airtight container.

Example 5

A low salt snack cracker is prepared as described in Example 4.

A cream cheese filling containing metformin (an antidiabetic agent) was prepared using a cream made from the following ingredients:

20	Fat (reduced fat spread rich in monounsaturates)	240g
	Lecithin	0.6g
	Cheese flavouring	2.0g
	Metformin	2.0g

The cream filling is added between two biscuit layers in an amount that provides 200 to 2000mg of metformin per sandwich biscuit. The biscuits are then stored in an airtight container.

It will, of course, be understood that the present invention has been described above purely by way of example and that modifications of detail can be made within the scope of this invention.

CLAIMS

1. A formulation for the administration of a medicinal substance comprising a sandwich biscuit comprising one or more biscuit layers that support filler layers wherein
5 the filler layer comprises a dosage unit form or multiple or sub-multiple layer thereof of an unpalatable medicament.
2. A formulation according to claim 1, in which the medicament has a gritty texture or a chalky texture or other unpleasant mouth feel.
- 10 3. A formulation according to claim 1 or 2, in which the medicament is present in an amount of greater than 500 mg per biscuit.
4. A formulation according to claim 3, in which the medicament is present in an
15 amount of between 1g and 3g per biscuit
5. A formulation according to any of the foregoing claims, in which the medicinal substance is selected from the ion exchange resin substance VML252, optionally in combination of calcium carbonate, the ion exchange resin cholestyramine, optionally in
20 combination chlofibrate, gemfibrozil and other orally active cholesterol-lowering materials, anthelmintic agents, metformin or gamma guanidinobutyramide and its pharmaceutically acceptable salts, optionally in combination of other oral agents used to treat diabetes type 2, carboxyl-methyl-cellulose and carboxyl-ethyl-cellulose, optionally in
25 suitable for treating elevated serum potassium, optionally in combination of with other oral agents used for treating elevated serum potassium.
6. A formulation according to claim 5, in which the anthelmintic agent is albendazole, febendazole, Ivermectin, thiabendazole and another bendazole substances
- 30 7. A formulation according to any of the foregoing claims comprising a biscuit layers comprise a medical substance, in which the medicinal substance in the biscuit and the medicament in the filler layer have a co-operating or synergistic effect on administration.

8. A formulation according to any of claims 1 to 6, in which the biscuit layer is an oatmeal biscuit and the medicament is a cholesterol lowering pharmaceutical.

9. A formulation according to claim 1, substantially as hereinbefore described in any
5 one of the Examples.

ABSTRACTFORMULATION FOR THE ADMINISTRATION OF
MEDICINAL SUBSTANCES

5

A formulation for administration of a medicinal substance, comprises a sandwich biscuit having two or more biscuit layers that support filler layer(s), in which the filler layer comprises a dosage unit form, or a multiple or sub-multiple thereof, of a medicament that is unpalatable in having, for example, a gritty texture or a chalky texture or other unpleasant mouth feel. The biscuit layer of the sandwich biscuit may be a plain, non-medicated, biscuit layer or may itself contain a medicament. In the latter instance, it is possible to select a different medicament for the filler layer from that in the biscuit layer, whereby the two medicaments have a co-operating or synergistic effect. The formulations also allow large dosages of drugs to be administered effectively in a palatable form and are suitable for the long-term administration of drugs.

20

25

30

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☒ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.